Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis
Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.
Asahi Kasei Acquires Calliditas Therapeutics for $1.1 Billion to Expand in Rare Disease Market
Asahi Kasei, Calliditas Therapeutics, acquisition, rare disease market, kidney disease, Tarpeyo, IgA nephropathy, pharmaceutical growth strategy
Revolutionizing CAR-Ts: The Future of Automation and Decentralization in Cell and Gene Therapy Manufacturing
Automation, Decentralization, CAR-Ts, Cell and gene therapy manufacturing, Advanced therapies, Personalized medicine, Regulatory compliance, Quality management systems, Supply chain logistics, Digital solutions, Real-time monitoring, Patient-centered care
Takeda Announces 641 Layoffs in Massachusetts Amid $900 Million Restructuring Campaign
Takeda, layoffs, Massachusetts, restructuring, pharmaceuticals, biotech, Cambridge, Lexington
NS Pharma’s Duchenne Muscular Dystrophy Therapy Viltepso Fails Confirmatory Trial
NS Pharma, Viltepso, Duchenne Muscular Dystrophy, Confirmatory Trial, Phase III, RACER53 Study, FDA Approval
Palleos Healthcare and OCT Global Unite to Form Comprehensive European Contract Research Organization ###
Palleos Healthcare, OCT Global, European CRO, Merger, Clinical Research, Contract Research Organization
Innovent to Submit IL-23 Psoriasis Drug to Chinese Regulators Following Phase 3 Success
Innovent, IL-23, psoriasis, picankibart, phase 3, China, regulatory submission, plaque psoriasis, CLEAR-1 study
BioNTech Strengthens ADC Partnership with China’s MediLink, Investing $25M Upfront
BioNTech, MediLink Therapeutics, Antibody-Drug Conjugate (ADC), Solid Tumors, TMALIN ADC Platform, Biotech Collaboration, China, Germany
NS Pharma’s Viltepso Fails Confirmatory Phase III Trial for Duchenne Muscular Dystrophy Treatment
Viltepso, NS Pharma, Duchenne muscular dystrophy, RACER53 study, viltolarsen, FDA approval, confirmatory trial, phase III trial, DMD treatment